Vasoactive Intestinal Peptide Tumor Market Report 2026

The vasoactive intestinal peptide tumor market size has grown strongly in recent years. It will grow from $1.61 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to improved detection of neuroendocrine tumors, increased availability of specialized oncology centers, growing use of imaging-based diagnostics, early adoption of somatostatin analog therapies, advancements in pancreatic surgery techniques.

The vasoactive intestinal peptide tumor market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising research investments in rare cancers, increasing development of novel targeted drugs, growing adoption of precision medicine approaches, expansion of specialized cancer care infrastructure, increasing awareness of rare endocrine disorders. Major trends in the forecast period include increasing adoption of targeted therapy approaches, rising use of advanced imaging for early diagnosis, growing focus on personalized treatment protocols, expansion of minimally invasive surgical techniques, enhanced integration of multidisciplinary care models.

The growing adoption of targeted therapy is expected to drive growth in the vasoactive intestinal peptide (VIP) tumor market in the coming years. Targeted therapies are treatments that act on specific molecules or pathways involved in disease progression, particularly in cancer, to selectively attack abnormal cells while minimizing damage to healthy cells. The increasing use of targeted therapies is fueled by precision medicine, which improves treatment efficacy by focusing on specific genetic mutations and reducing side effects. Targeted therapies for VIP tumors work by blocking key pathways that promote tumor growth and hormone secretion, helping to lower VIP levels, alleviate symptoms such as severe diarrhea, and slow disease progression. For instance, in July 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, 76 gene therapy trials were initiated in the second quarter of 2024, representing a 25% increase compared to the previous quarter. Therefore, the rise in targeted therapy is supporting growth in the vasoactive intestinal peptide tumor market.

The increasing incidence of neuroendocrine tumors is also expected to propel growth in the vasoactive intestinal peptide tumor market. Neuroendocrine tumors (NETs) are a group of rare, slow-growing cancers that arise from neuroendocrine cells, which exhibit characteristics of both nerve cells and hormone-producing cells. The rising incidence of NETs is attributed to improved diagnostic techniques that enable earlier and more accurate detection of these tumors, which were previously underdiagnosed. Vasoactive intestinal peptide (VIP) tumors are a rare subtype of NETs marked by excessive VIP secretion, causing severe watery diarrhea and electrolyte imbalances. For instance, in August 2025, data from the American Cancer Society, a US-based professional organization, reported that roughly 8,000 neuroendocrine tumors originating in the gastrointestinal tract - including the stomach, intestines, appendix, colon, or rectum - are diagnosed annually in the United States. The reported annual incidence of NETs is approximately 1 to 2 cases per 100,000 people. Therefore, the increasing incidence of neuroendocrine tumors is driving growth in the vasoactive intestinal peptide tumor market.

Major companies operating in the vasoactive intestinal peptide tumor market are concentrating on the development of advanced therapies, such as long-acting injectable suspensions, to improve treatment efficacy, enhance patient adherence, and provide sustained symptom relief. Long-acting injectable suspensions are formulations designed to release active ingredients gradually over time, reducing the need for frequent dosing. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., a US-based pharmaceutical company, launched the first and only generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the United States. This medication is used for long-term maintenance therapy in acromegaly patients who have an inadequate response to surgery or radiotherapy, and it also treats severe diarrhea and flushing associated with metastatic carcinoid tumors and VIP-secreting tumors. The launch reinforces Teva’s expertise in complex generics and supports its goal of maintaining a strong position in the generic pharmaceuticals market.

Major companies operating in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, Ganesh Diagnostic, Ipsen Pharma SA, F Hoffmann‑La Roche Ltd, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bristol‑Myers Squibb Company, Merck & Co.

North America was the largest region in the vasoactive intestinal peptide tumor market in 2025. The regions covered in the vasoactive intestinal peptide tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vasoactive intestinal peptide tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the vasoactive intestinal peptide tumor market by increasing costs associated with imported diagnostic imaging systems, radiotherapy equipment, specialized surgical tools, and targeted pharmaceutical inputs. Hospitals and cancer specialty clinics in North America and Europe are most affected due to reliance on advanced imported medical technologies, while Asia-Pacific faces higher costs for oncology drug manufacturing and equipment procurement. These tariffs are contributing to higher treatment costs and longer procurement timelines. However, they are also encouraging local manufacturing of diagnostic devices, regional pharmaceutical production, and increased domestic investment in oncology treatment capabilities.

The vasoactive intestinal peptide tumor market research report is one of a series of new reports that provides vasoactive intestinal peptide tumor market statistics, including vasoactive intestinal peptide tumor industry global market size, regional shares, competitors with a vasoactive intestinal peptide tumor market share, detailed vasoactive intestinal peptide tumor market segments, market trends and opportunities, and any further data you may need to thrive in the vasoactive intestinal peptide tumor industry. This vasoactive intestinal peptide tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A vasoactive intestinal peptide (VIP) tumor, also called VIPoma, is a rare neuroendocrine tumor that usually develops in the pancreas. It produces excessive amounts of VIP, causing severe watery diarrhea, dehydration, and electrolyte disturbances. Diagnosis is confirmed by elevated VIP levels in the blood, and treatment may include surgery, medications, or targeted therapies.

The main treatment approaches for vasoactive intestinal peptide tumors include surgical intervention, radiotherapy, chemotherapy, and targeted therapy. Surgical intervention aims to safely remove localized tumors, alleviate symptoms, and prevent complications through complete or minimally invasive resection. Diagnosis is made using various methods such as imaging techniques, biopsy, and endoscopic ultrasound, and treatments may include palliative care, curative approaches, or adjuvant therapy. End users include hospitals, cancer specialty clinics, and diagnostic laboratories.

The vasoactive intestinal peptide tumor market consists of revenues earned by entities by providing services such as genetic testing, immunotherapy, hormone therapy, nuclear medicine, personalized medicine, palliative care, clinical trials, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasoactive intestinal peptide (VIP) Tumor market also includes sales of diagnostic kits, biopsy needles, imaging systems, radiation therapy equipment, chemotherapy drugs, targeted therapy drugs, surgical instruments, and supportive care medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.